Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02743793
Other study ID # DAIT ITN063ST
Secondary ID UM1AI109565
Status Terminated
Phase
First received
Last updated
Start date June 30, 2016
Est. completion date March 24, 2020

Study information

Verified date August 2021
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ. Some organ transplant recipients can stop taking anti-rejection medicines without rejecting their transplanted organ (this is called 'tolerance'). The purpose of this study will collect samples and data from 'tolerant' liver or kidney transplant recipients in order to find out: The purpose of this study is to collect samples and data in order to find out: - How long liver or kidney transplant recipients can remain tolerant; - What happens in the tolerant recipient's body over time; and - If there are patterns in the body that are linked to tolerance.


Description:

This is a multi-center, prospective, observational study in which operationally tolerant recipients of liver or kidney allografts will be followed longitudinally, with annual collections of clinical data and biological samples. All participants will be followed for the duration of the study, regardless of changes in their tolerance status. Participants will be recruited by three main pathways: 1. Tolerant participants from current and past Immune Tolerance Network (ITN) trials, including those who have already completed trial participation and those who are anticipated to complete trial participation, 2. Tolerant participants referred by ITN affiliated investigators, academic and community transplant physicians and directly through outreach to transplant affinity groups such as the National Kidney Foundation (NKF), and 3. Tolerant participants from the general transplant community who are reachable through general contact channels such as the ITN website, word-of-mouth referrals from existing participants, and social media.


Recruitment information / eligibility

Status Terminated
Enrollment 41
Est. completion date March 24, 2020
Est. primary completion date March 24, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Recipient of single organ liver or kidney allograft from a living or deceased donor; - At screening, operationally tolerant, as defined by: - Absence of any immunosuppressive therapy for =52 weeks prior to the screening visit, and - No evidence of allograft rejection in the 52 weeks prior to the screening visit, based on the allograft recipient's medical history. - Normal allograft function, defined as: - For liver transplant recipients: Liver function tests (ALT, GGT) both less than or equal to the upper limit of normal (ULN); and, - For kidney transplant recipients: Serum creatinine value corresponds to an estimated GFR > 45 ml/min/1.73 m^2. - Receiving regular follow-up for a kidney or liver transplant by a local physician: --Participants must be willing to allow the study team to contact and share medical information with this local physician. - Ability to sign informed consent. Exclusion Criteria: - Current malignancy requiring recent surgery, ongoing chemotherapy, or radiation; - Transplant of another organ; - Current drug or alcohol dependency; - Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; and - Inability to comply with the study visit schedule and required assessments.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Blood Draw


Locations

Country Name City State
United States Emory University School of Medicine Atlanta Georgia
United States Ann & Robert H. Lurie Children's Memorial Hospital of Chicago Chicago Illinois
United States University of Pennsylvania Medical Center Philadelphia Pennsylvania
United States Children's Hospital of Pittsburg of UPMC Pittsburgh Pennsylvania
United States University of California, San Francisco San Francisco California

Sponsors (4)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network (ITN), PPD, Rho Federal Systems Division, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Loss of Operational Tolerance A participant is considered to have operational tolerance if they are off all immunosuppression medication while continuing to have stable allograft function and no rejection. For these participants, the date of operational tolerance is considered as 52 weeks from the participant's last documented dose of immunosuppression. A participant will be considered to have lost operational tolerance if they experience rejection, have loss of stable allograft function (in the absence of confounding factors), or restart immunosuppression. The endpoint was analyzed using Kaplan-Meier survival estimate and associated two-sided 95% confidence interval, using a delayed-entry model with left-truncation of survival times by censoring the time from achieving operational tolerance at the time of study enrollment. The survival estimate is at the time of the last of event. From operational tolerance to ITN063ST study completion, assessed up to 60 months
Secondary Time to Development of Anti-Human Leukocyte Antigen (HLA) Antibody or Donor Specific Antibodies (DSA) Time to development of either:
de novo HLA antibodies (anti-HLA Ab) post-transplant. Alloantibody is defined as an antibody produced following the introduction of an alloantigen into the system of an individual lacking that particular antigen; OR
Donor Specific Antibodies (DSA), a newly developed alloantibody that is against the donor organ.
Alloantibodies are important mediators of acute and chronic rejection.
**These data are not yet available.**
Day 0 (Study Enrollment) to Study Completion (Up to 3.7 years)
Secondary Number of Participants With Biopsy-Proven or Clinical Acute Rejection, Steroid Resistant Rejection and/or Chronic Rejection Number of participants with acute rejection, steroid resistant rejection and/or chronic rejection.
Criteria employed for acute and chronic rejection: Banff guidelines.
Day 0 (Study Enrollment) to Study Completion (Up to 3.7 years)
Secondary Number of Participants With Graft Loss, Not Including Death With a Functioning Graft A participant is considered to have graft loss when the participant is retransplanted with another donor kidney, relisted for transplantation, or dies with a non-functioning graft. Day 0 (Study Enrollment) to Study Completion (Up to 3.7 years)
See also
  Status Clinical Trial Phase
Completed NCT04087720 - Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney Transplant Phase 4
Completed NCT03749356 - Study to Evaluate the Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant Recipients Phase 4
Withdrawn NCT05811468 - Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
Completed NCT03527238 - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine Phase 2
Completed NCT00498576 - Melatonin and Adiponectin in Hypertensive Kidney Transplant N/A
Completed NCT00642655 - Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation Phase 1/Phase 2
Completed NCT00374400 - The Paired Donation Consortium Paired Donation Program N/A
Completed NCT01710033 - A Study Of CP-690,550 In Stable Kidney Transplant Patients Phase 1
Completed NCT00205257 - Prediction of Acute Rejection in Renal Transplant Phase 1
Completed NCT02711826 - Treg Therapy in Subclinical Inflammation in Kidney Transplantation Phase 1/Phase 2
Withdrawn NCT03978494 - Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients. Phase 1
Completed NCT03837522 - Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies N/A
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed NCT05029310 - Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients Phase 4
Completed NCT03644485 - Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients Phase 4
Active, not recruiting NCT02409901 - Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients N/A
Completed NCT01047410 - ACtive Care After Transplantation, the ACT Study N/A
Completed NCT00940940 - Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation Phase 4
Completed NCT00217126 - The Study of Long-term Deterioration of Kidney Transplants. Phase 4
Completed NCT00270712 - A Study of Factors That Affect Long-Term Kidney Transplant Function